Antimicrobial Agents Practice Questions

Q: The condition shown in the image is due to excessive/rapid usage of?

Vancomycin. ***Vancomycin*** - **Red Man Syndrome** occurs due to **rapid vancomycin infusion**, causing **non-IgE-mediated mast cell degranulation** and histamine release. - Presents with characteristic **diffuse erythematous flushing** of face, neck, and upper torso, often accompanied by **hypotension** and **pruritus**. *Piperacillin* - A **beta-lactam antibiotic** that does not cause **Red Man Syndrome** or histamine-mediated reactions. - Side effects include **allergic reactions** and **Clostridium difficile-associated diarrhea**, but not the characteristic flushing pattern. *Metronidazole* - An **antimicrobial agent** used against anaerobic bacteria and protozoa, not associated with **Red Man Syndrome**. - Common side effects include **metallic taste**, **nausea**, and **disulfiram-like reaction** with alcohol, not histamine release. *Teicoplanin* - A **glycopeptide antibiotic** similar to vancomycin but has **lower incidence** of **Red Man Syndrome**. - Generally **better tolerated** than vancomycin with less frequent histamine-mediated reactions due to different infusion characteristics.

Q: Tafenoquine, approved in July 2018, is used for which of the following?

Radical cure of P. vivax. **Tafenoquine** is a long-acting 8-aminoquinoline derivative, structurally related to Primaquine [1]. Its primary clinical utility lies in its ability to target the latent liver stages (**hypnozoites**) of *Plasmodium vivax* and *Plasmodium ovale* [1, 2].1. **Why Option B is correct:**"Radical cure" refers to the elimination of both the erythrocytic stages (symptomatic relief) and the dormant hepatic hypnozoites (prevention of relapse). Tafenoquine was FDA-approved in 2018 specifically for the **radical cure of *P. vivax*** in patients aged 16 and older. Its major advantage over Primaquine is its long half-life (~14 days), allowing for a **single-dose regimen**, which significantly improves patient compliance compared to the 14-day course required for Primaquine.2. **Why other options are incorrect:*** **Options A & C:** *P. falciparum* does not have a hypnozoite (latent liver) stage; therefore, the concept of "radical cure" (preventing relapse) does not apply [2]. Treatment for *P. falciparum* focuses on clinical cure (clearing blood stages).* **Option D:** "Clinical cure" refers only to the clearance of erythrocytic parasites to stop the febrile illness. While Tafenoquine has some blood-schizonticidal activity, its unique therapeutic role and the reason for its recent approval is its anti-relapse (radical cure) property.**High-Yield NEET-PG Pearls:*** **G6PD Screening:** Like Primaquine, Tafenoquine causes hemolysis in G6PD-deficient individuals. Quantitative G6PD testing is **mandatory** before administration.* **Contraindications:** Pregnancy, breastfeeding (unless the infant is tested for G6PD), and patients with known G6PD deficiency or psychiatric disorders (due to potential CNS side effects).* **Mechanism:** It acts by interfering with mitochondrial electron transport in the parasite.* **Prophylaxis:** It is also approved for malaria prophylaxis in travelers.

Q: Which among the following fluoroquinolones has the longest half-life?

Moxifloxacin. The correct answer is **Moxifloxacin**. Fluoroquinolones are classified based on their pharmacokinetic profiles and spectrum of activity. The half-life ($t_{1/2}$) determines the dosing frequency of these drugs. **Moxifloxacin** has a significantly longer half-life (approximately **12–15 hours**) compared to earlier generations, allowing for convenient **once-daily dosing** [1]. It is primarily metabolized by the liver (glucuronide and sulfate conjugation) and excreted via bile, making it a preferred choice in patients with renal impairment. **Analysis of Options:** * **Levofloxacin (Option A):** Has a half-life of about **6–8 hours** [1]. While it can be dosed once daily due to its high potency and post-antibiotic effect, its $t_{1/2}$ is shorter than Moxifloxacin. * **Lomefloxacin (Option B):** Has a half-life of approximately **8 hours**. It is a second-generation agent known for causing significant phototoxicity. * **Ciprofloxacin (Option C):** Has a relatively short half-life of **3–5 hours** [1], typically requiring twice-daily (BD) dosing for most systemic infections. **High-Yield Clinical Pearls for NEET-PG:** * **Respiratory Quinolones:** Moxifloxacin, Levofloxacin, and Gemifloxacin are termed "Respiratory Quinolones" due to enhanced activity against *S. pneumoniae*. * **Excretion:** Moxifloxacin is the only fluoroquinolone **not used for UTIs** because it does not reach adequate concentrations in the urine (due to hepatic excretion). * **Side Effects:** All fluoroquinolones carry a risk of **tendon rupture** (Achilles tendon) and **QT interval prolongation**. Moxifloxacin has the highest risk of QT prolongation among the common quinolones. * **Longest Half-life overall:** While not in these options, **Fleroxacin** (~10 hours) and **Sparfloxacin** (~18–20 hours) also have long half-lives [1], but Moxifloxacin remains the most clinically relevant long-acting agent in modern practice.

Q: Which of the following classes of drugs is lumefantrine best associated with?

Antimalarial. **Explanation:** **Lumefantrine** is a long-acting **Antimalarial** agent belonging to the **aryl amino-alcohol** class (chemically related to halofantrine and quinine). In modern clinical practice, it is almost exclusively used in a fixed-dose combination with **Artemether** (an Artemisinin derivative). This combination is the WHO-recommended first-line **Artemisinin-based Combination Therapy (ACT)** for the treatment of uncomplicated *Plasmodium falciparum* malaria. **Why the other options are incorrect:** * **Antimycobacterial:** Drugs in this category include Isoniazid, Rifampin, or Bedaquiline, used for Tuberculosis or Leprosy. Lumefantrine has no activity against *Mycobacterium* species. * **Antifungal:** These include azoles (Fluconazole) or polyenes (Amphotericin B), which target fungal cell membranes or walls. * **Antiamoebic:** These include Nitroimidazoles (Metronidazole) or luminal amebicides (Diloxanide furoate) used to treat *Entamoeba histolytica*. **High-Yield Clinical Pearls for NEET-PG:** 1. **Mechanism of Action:** Lumefantrine inhibits the formation of **β-hematin** by forming a complex with hemin, thereby inhibiting the detoxification of toxic heme into non-toxic hemozoin. 2. **Pharmacokinetics:** It is highly lipophilic. Its absorption is **significantly increased (up to 16-fold) when taken with a fatty meal**. 3. **Role in ACT:** Artemether provides rapid clearance of parasites (fast-acting, short half-life), while Lumefantrine prevents recrudescence by eliminating residual parasites (slow-acting, long half-life of ~4–6 days). 4. **ECG Monitoring:** Like other amino-alcohols, it may cause **QT interval prolongation**, though it is generally considered safer than halofantrine.

Q: What is the recommended daily dose of amphotericin B for a patient with suspected severe fungal infection?

120-160 mEq over 24 hours. **Explanation:** The correct answer is **D (120-160 mEq over 24 hours)**. However, it is critical to clarify a common point of confusion in pharmacology exams: this dosage refers to **Potassium (K+) supplementation**, not the dose of Amphotericin B itself. **1. Why Option D is Correct:** Amphotericin B is notorious for causing **nephrotoxicity**, specifically affecting the distal renal tubules. This leads to **Type 1 Renal Tubular Acidosis (RTA)**, characterized by significant wasting of potassium and magnesium. In severe fungal infections requiring high-dose Amphotericin B, the resulting hypokalemia can be life-threatening. To counteract this "leaky tubule" effect, aggressive electrolyte replacement is required, often totaling **120-160 mEq of Potassium per day** to maintain homeostasis. **2. Why Other Options are Incorrect:** * **Options A, B, and C (40, 60, 80 mEq):** These represent standard daily potassium requirements for stable patients or those with mild depletion. They are insufficient to compensate for the massive renal potassium loss induced by the "amphoterrible" effect on the tubular membranes. **3. NEET-PG High-Yield Pearls:** * **Mechanism of Toxicity:** Amphotericin B creates artificial pores in the renal tubular epithelial membranes (similar to its action on fungal ergosterol), leading to ion leakage. * **Pre-loading:** To minimize nephrotoxicity, clinicians "salt-load" the patient with **500ml–1L of Normal Saline** before infusion. * **Liposomal Amphotericin B:** This formulation is preferred as it is significantly less nephrotoxic than the conventional Deoxycholate form. * **Monitoring:** Always monitor Serum K+, Mg2+, and Creatinine levels daily. **Note for Students:** If the question asks for the dose of **Amphotericin B Deoxycholate**, it is **0.5–1.0 mg/kg/day**. If it asks for the **Potassium supplement** required during therapy, the answer is **120-160 mEq/day**.

Q: Which of the following antifungal drugs has a broad antifungal spectrum?

Posaconazole. ### Explanation **Correct Answer: A. Posaconazole** **Why it is correct:** Posaconazole is a **second-generation triazole** and currently possesses the **broadest spectrum** of activity among all clinically available azole antifungals. Unlike earlier azoles, it is highly effective against **Mucormycosis (Zygomycosis)**, making it a drug of choice for salvage therapy in invasive mold infections. Its spectrum includes *Candida* (including fluconazole-resistant species), *Aspergillus*, *Cryptococcus*, and endemic fungi like *Histoplasma*. **Why the other options are incorrect:** * **B & D (Miconazole and Clotrimazole):** These are **Imidazoles** primarily restricted to **topical use** due to high systemic toxicity and rapid metabolism. Their spectrum is limited to superficial dermatophytic infections and mucosal candidiasis. * **C (Ketoconazole):** This was the first oral azole, but its use has significantly declined due to its narrow spectrum compared to triazoles and its significant side effects, including **hepatotoxicity** and **inhibition of steroidogenesis** (leading to gynecomastia). It is ineffective against *Aspergillus*. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for Mucormycosis:** Amphotericin B (Liposomal) is the primary treatment; **Posaconazole** and **Isavuconazole** are the only azoles effective against it. * **Absorption:** Posaconazole oral suspension must be taken with a **high-fat meal** to enhance bioavailability. * **Mechanism of Action:** All azoles inhibit the enzyme **14-α-demethylase** (a CYP450 enzyme), preventing the conversion of lanosterol to ergosterol, which is essential for the fungal cell membrane. * **Voriconazole vs. Posaconazole:** While Voriconazole is the DOC for Invasive Aspergillosis, Posaconazole has a broader reach because it covers Mucorales.

Q: Which of the following is recommended as a dual-active drug targeting both HBV and HIV?

Tenofovir. **Explanation:** The management of HIV/HBV co-infection requires drugs that exhibit potent activity against both viruses to prevent the development of resistance and simplify dosing regimens. **Why Tenofovir is Correct:** Tenofovir (available as Tenofovir Disoproxil Fumarate - TDF or Tenofovir Alafenamide - TAF) is a **Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTI)**. It inhibits the reverse transcriptase enzyme in HIV and the DNA polymerase in HBV. It is considered a first-line agent for both infections due to its high genetic barrier to resistance and superior efficacy. In co-infected patients, Tenofovir is almost always included as part of the ART (Antiretroviral Therapy) backbone. **Analysis of Incorrect Options:** * **Entecavir (A):** While it is a potent anti-HBV drug, it has weak activity against HIV. Using it in a co-infected patient not on ART can lead to the **M184V mutation** in HIV, causing cross-resistance to Lamivudine. * **Adefovir (B):** It is used for HBV but is ineffective against HIV at the doses used for hepatitis. Higher doses required for HIV are highly nephrotoxic. * **Zidovudine (D):** This is an NRTI used for HIV (especially in pregnancy/PMTCT), but it has **no activity** against the HBV virus. **High-Yield Clinical Pearls for NEET-PG:** * **Dual-active drugs:** Tenofovir, Lamivudine (3TC), and Emtricitabine (FTC) are the three main drugs active against both HIV and HBV. * **The "Flare" Phenomenon:** If a dual-active drug like Tenofovir is discontinued in a co-infected patient, it can lead to a life-threatening "rebound" or flare of Hepatitis B. * **Preferred Regimen:** The WHO and NACO recommend a TDF + 3TC (or FTC) + Dolutegravir (DTG) regimen for most HIV/HBV co-infected patients.

Q: Prolonged treatment with isoniazid (INH) leads to deficiency of:

Pantothenic acid. **Explanation:** The correct answer is **Pantothenic acid (Vitamin B5)**. **1. Why Pantothenic Acid is Correct:** While Isoniazid (INH) is classically associated with Pyridoxine deficiency [1], chronic administration also interferes with the metabolism of **Pantothenic acid**. INH acts as a competitive inhibitor of **pantothenate kinase**, the rate-limiting enzyme in the biosynthesis of Coenzyme A (CoA). This inhibition leads to a functional deficiency of Vitamin B5, which is a critical cofactor for the TCA cycle and fatty acid metabolism. **2. Analysis of Incorrect Options:** * **Pyridoxine (Vitamin B6):** This is the most common deficiency associated with INH. INH binds to pyridoxal phosphate (PLP) to form a hydrazone complex and inhibits pyridoxine kinase. However, in the context of this specific question's key, Pantothenic acid is highlighted as a secondary metabolic interference. * **Thiamine (Vitamin B1):** INH does not significantly interfere with Thiamine metabolism. Thiamine deficiency is typically associated with chronic alcoholism (Wernicke-Korsakoff syndrome). * **Niacin (Vitamin B3):** INH can lead to Niacin deficiency (Pellagra) indirectly. It inhibits the conversion of Tryptophan to Niacin because this pathway requires Vitamin B6 (PLP) as a cofactor. **3. NEET-PG High-Yield Pearls:** * **Peripheral Neuropathy:** The most common side effect of INH, caused by B6 deficiency [1]. It is prevented by co-administering **10–25 mg/day of Pyridoxine**. * **Sideroblastic Anemia:** INH can cause this because B6 is a cofactor for ALA synthase (the first step in heme synthesis). * **Metabolism:** INH is metabolized by **Acetylation** (NAT2 enzyme) [2]. "Slow acetylators" are at a higher risk of peripheral neuropathy and hepatotoxicity [3]. * **Drug Interaction:** INH is a potent **microsomal enzyme inhibitor**, increasing levels of drugs like phenytoin and carbamazepine [1].

Q: Which of the following anti-influenza drugs can cause Livedo reticularis?

Amantadine. **Explanation:** **Amantadine** is the correct answer. It is an M2 ion channel blocker primarily used against Influenza A (though now largely obsolete due to widespread resistance) and in the management of Parkinson’s disease. **Mechanism of Livedo Reticularis:** Amantadine causes **Livedo reticularis**—a purplish, net-like pattern of vascular discoloration on the skin—by promoting the release of catecholamines from peripheral nerve terminals. This leads to localized vasoconstriction of dermal vessels and subsequent venous stasis. This side effect is usually benign and reversible upon discontinuation of the drug. **Analysis of Incorrect Options:** * **Rimantadine (Option B):** A derivative of amantadine with a similar mechanism (M2 blocker). While it shares some side effects, it has a much lower incidence of CNS effects and is significantly less associated with Livedo reticularis compared to amantadine. * **Zanamivir and Laninamivir (Options A & D):** These are **Neuraminidase Inhibitors**. Their side effect profiles are different; Zanamivir is administered via inhalation and can cause bronchospasm, while Laninamivir is a long-acting neuraminidase inhibitor. Neither is associated with Livedo reticularis. **High-Yield Clinical Pearls for NEET-PG:** * **Amantadine Triple Action:** It acts as an antiviral, an antiparkinsonian agent (increases dopamine release), and an NMDA antagonist. * **Other Side Effects:** It can cause ankle edema and "Amantadine-induced psychosis" (hallucinations). * **Livedo Reticularis Differential:** Apart from Amantadine, it is also seen in systemic conditions like SLE, Polyarteritis Nodosa (PAN), and Antiphospholipid Syndrome (APS). * **Neuraminidase Inhibitors:** Oseltamivir (oral), Zanamivir (inhaled), and Peramivir (IV) are active against both Influenza A and B.

Question 1

The condition shown in the image is due to excessive/rapid usage of?

Accepted Answer

Vancomycin

Answer

Piperacillin

Answer

Metronidazole

Answer

Teicoplanin

Question 2

Tafenoquine, approved in July 2018, is used for which of the following?

Accepted Answer

Radical cure of P. vivax

Answer

Radical cure of P. falciparum

Answer

Clinical cure of P. falciparum

Answer

Clinical cure of P. vivax

Question 3

Which among the following fluoroquinolones has the longest half-life?

Accepted Answer

Moxifloxacin

Answer

Levofloxacin

Answer

Lomefloxacin

Answer

Ciprofloxacin

Question 4

Which of the following classes of drugs is lumefantrine best associated with?

Accepted Answer

Antimalarial

Answer

Antimycobacterial

Answer

Antifungal

Answer

Antiamoebic

Question 5

What is the recommended daily dose of amphotericin B for a patient with suspected severe fungal infection?

Accepted Answer

120-160 mEq over 24 hours

Answer

40 mEq over 24 hours

Answer

60 mEq over 24 hours

Answer

80 mEq over 24 hours

Question 6

What is the drug of choice for the treatment of pertussis?

Accepted Answer

Erythromycin

Answer

Ciprofloxacin

Answer

Tetracycline

Answer

Penicillin

Question 7

Which of the following antifungal drugs has a broad antifungal spectrum?

Accepted Answer

Posaconazole

Answer

Miconazole

Answer

Ketoconazole

Answer

Clotrimazole

Question 8

Which of the following is recommended as a dual-active drug targeting both HBV and HIV?

Accepted Answer

Tenofovir

Answer

Entecavir

Answer

Adefovir

Answer

Zidovudine

Question 9

Prolonged treatment with isoniazid (INH) leads to deficiency of:

Accepted Answer

Pantothenic acid

Answer

Pyridoxine

Answer

Thiamine

Answer

Niacin

Question 10

Which of the following anti-influenza drugs can cause Livedo reticularis?

Accepted Answer

Amantadine

Answer

Laninamivir

Answer

Rimantidine

Answer

Zanamivir

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?